Global Maternal Blood Test Market, By Type (Combined First Trimester Screening, Second Trimester Maternal Serum Screening), Tested Conditions (Edwards Syndrome, Patau Syndrome, Down syndrome, Neural Tube Defects), End-User (Diagnostic Laboratories, Hospitals) – Industry Trends and Forecast to 2030.
Maternal Blood Test Market Analysis and Size
One of the major factors driving the growth of the maternal blood test market is the continuous improvement in the reimbursement scenario for NIPT around the world. An increase in the incidence of chromosomal abnormalities, combined with increasing product usage in new applications, drive market growth. The growing preference for non-invasive techniques over invasive methods, as well as an increase in programmes aimed at raising NIPT awareness, all have an impact on the market.
Data Bridge Market Research analyses that the maternal blood test market which was USD 3.807 billion in 2022, is expected to reach USD 10.12 billion by 2030, at a CAGR of 13.00% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Maternal Blood Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Combined First Trimester Screening, Second Trimester Maternal Serum Screening), Tested Conditions (Edwards Syndrome, Patau Syndrome, Down syndrome, Neural Tube Defects), End- User (Diagnostic Laboratories, Hospitals)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
CENTOGENE N.V. (Germany), SEQUENOM (U.S.), Natera, Inc. (U.S.), LifeLabs Genetics (Canada), Sema4 OpCo, Inc. (U.S.), Invitae Corporation (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), General Electric (U.S.), PerkinElmer Inc. (U.S.), Agilent Technologies, Inc. (U.S.), BGI (China), F. Hoffmann-La Roche Ltd (Switzerland), YOURGENE HEALTH (U.K.), Eurofins Scientific (Luxembourg), EKF Diagnostics (Germany)
|
|
Market Opportunities
|
|
Market Definition
A maternal blood test is a type of prenatal screening test that determines the likelihood that a chromosome disorder will impact a pregnancy or certain behavioural issues will impact a pregnancy. The primary goal of the test is to ensure that the baby does not have any chromosomal abnormalities such as Down syndrome. These tests are known to be capable of providing more information about pregnancy health.
Global Maternal Blood Test Market Dynamics
Drivers
- Rising use of maternal blood tests
Maternal blood tests can detect and diagnose chromosomal rearrangements, X-linked diseases, and aid in the reduction of spontaneous abortions, increased implantation rates, the prevention of trisomic offspring, and the avoidance of the risk of transmitting single gene disorders. However, PGS and PGD results are not 100% accurate, and if necessary, diagnostic tests such as amniocentesis and CVS must be performed after pregnancy to confirm the positive PGS/PGD results. In the United States alone, more than 63,000 babies were born through IVF in 2013, an increase of 2,000 births from 2012. These are the certain test that help the market to grow.
Opportunities
- Introduction of NIPTs
The introduction of NIPTs using cell-free foetal DNA (cffDNA) in 2011 was the most significant advancement in the field of prenatal screening. Obstetricians and patients who are put off by ultrasound screening's 10% to 15% false positive rate and maternal serum test's 5% false positive rate are eagerly embracing NIPTs that claim to have only a 5% false positive rate. In just four years, molecular genetics companies have successfully developed eight different types of kits for detecting genetic abnormalities in foetus. These products have gradually marginalized maternal serum tests, and maternal serum tests are expected to become obsolete within the next decade.
Restraints/Challenges
- Lack of skilled professionals
Lack of skilled and trained professionals, strict regulatory guidelines and ethical stumbling blocks limits the market's growth during the forecast period.
This maternal blood test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the maternal blood test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Maternal Blood Test Market Scope
The maternal blood test market is segmented on the basis of type, tested condition and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Combined First Trimester Screening
- Second Trimester Maternal Serum Screening
Tested Conditions
- Edwards Syndrome
- Patau Syndrome
- Down syndrome
- Neural Tube Defects
End-User
- Diagnostic Laboratories
- Hospitals
Maternal Blood Test Market Regional Analysis/Insights
The maternal blood test market is analyzed and market size insights and trends are provided by country, type, tested condition and end-user as referenced above.
The countries covered in the maternal blood test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the maternal blood test market because of the high adoption of advanced technologies within the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the developing healthcare infrastructure, and increasing awareness programs and conferences in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The maternal blood test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for maternal blood test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the maternal blood test market. The data is available for historic period 2011-2021.
Competitive Landscape and Maternal Blood Test Market Share Analysis
The maternal blood test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to maternal blood test market.
Some of the major players operating in the maternal blood test market are:
- CENTOGENE N.V. (Germany)
- SEQUENOM (U.S.)
- Natera, Inc. (U.S.)
- LifeLabs Genetics (Canada)
- Sema4 OpCo, Inc. (U.S.)
- Invitae Corporation (U.S.)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- General Electric (U.S.)
- PerkinElmer Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- BGI (China)
- F. Hoffmann-La Roche Ltd (Switzerland)
- YOURGENE HEALTH (U.K.)
- Eurofins Scientific (Luxembourg)
- EKF Diagnostics (Germany)
SKU-